Assignee
ALTEOGEN INC
KR·12 granted patents·10 pending applications·38 citations·filing 2013–2025
Top patents by PatentIndex Score
22 records- 0194US9982032B2Stable liquid formulation of fusion protein with IgG Fc domainALTEOGEN INC·Filed 2016·Granted May 29, 2018·19 cites·4 claims
- 0287US9474803B2Composition for stabilizing fusion protein in which protein and FC domain are fusedALTEOGEN INC·Filed 2013·Granted Oct 25, 2016·5 cites·7 claims
- 0385US9814782B2Modified antibody in which motif comprising cysteine residue is bound, modified antibody-drug conjugate comprising the modified antibody, and production method for sameALTEOGEN INC·Filed 2013·Granted Nov 14, 2017·10 cites·16 claims
- 0477US12371683B2Hyaluronidase variants and pharmaceutical composition comprising the sameALTEOGEN INC·Filed 2019·Granted Jul 29, 2025·1 cites·49 claims
- 0575US11235065B2Antibody-drug conjugate comprising modified antibodyALTEOGEN INC·Filed 2017·Granted Feb 1, 2022·2 cites·12 claims
- 0675US2025129352A1Method for producing recombinant hyaluronidaseALTEOGEN INC·Filed 2024·Application pending·0 cites
- 0775US2025136964A1Method for producing recombinant hyaluronidaseALTEOGEN INC·Filed 2024·Application pending·0 cites
- 0872US11414476B2Method for producing fusion protein having IgG Fc domainALTEOGEN INC·Filed 2016·Granted Aug 16, 2022·1 cites·14 claims
- 0968US2025368976A1Novel hyaluronidase variants and pharmaceutical composition containing the sameALTEOGEN INC·Filed 2025·Application pending·0 cites
- 1065US12090210B2Antibody-drug conjugate comprising modified antibodyALTEOGEN INC·Filed 2021·Granted Sep 17, 2024·0 cites·11 claims
- 1164US12221638B2Method for producing recombinant hyaluronidaseALTEOGEN INC·Filed 2021·Granted Feb 11, 2025·0 cites·15 claims
- 1262US2022348636A1Method for producing fusion protein having igg fc domainALTEOGEN INC·Filed 2022·Application pending·0 cites
- 1362US2022289864A1Pharmaceutical composition for subcutaneous injection comprising human hyaluronidase ph20 variant and drugALTEOGEN INC·Filed 2022·Application pending·0 cites
- 1460US12570766B2Pharmaceutical composition for subcutaneous administration containing human hyaluronidase PH20 variant and drugALTEOGEN INC·Filed 2020·Granted Mar 10, 2026·0 cites·148 claims
- 1559US2025122492A1N-terminal and/or C-terminal Cleaved Soluble PH20 Polypeptide and Use ThereofALTEOGEN INC·Filed 2023·Application pending·0 cites
- 1656US11866492B2Antibody specifically binding to FOLR1 and uses thereofALTEOGEN INC·Filed 2019·Granted Jan 9, 2024·0 cites·10 claims
- 1755US2025243240A1Method for purifying fusion protein having igg fc domainALTEOGEN INC·Filed 2022·Application pending·0 cites
- 1852US2023250408A1Novel hyaluronidase variants with improved stability and pharmaceutical composition comprising the sameALTEOGEN INC·Filed 2021·Application pending·0 cites
- 1952US2025009850A1Pharmaceutical composition comprising human hyaluronidase ph20 and drugALTEOGEN INC·Filed 2022·Application pending·0 cites
- 2049US9821059B2Composition for stabilizing protein and pharmaceutical formulation comprising the sameALTEOGEN INC·Filed 2015·Granted Nov 21, 2017·0 cites·6 claims
- 2148US2017119903A1Modified antibody in which motif comprising cysteine residue is bound, modified antibody-drug conjugate comprising the modified antibody, and production method for sameALTEOGEN INC·Filed 2016·Application pending·0 cites
- 2241US11981719B2Growth hormone receptor antagonists and fusion proteins thereofALTEOGEN INC·Filed 2018·Granted May 14, 2024·0 cites·15 claims
Join the waitlist — get patent alerts
Get an alert when ALTEOGEN INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →